Sangamo Therapeutics, Inc.
PROGRAMMED CELL DEATH 1 (PD1) SPECIFIC NUCLEASES

Last updated:

Abstract:

Described herein are engineered nucleases specific for PD1 gene target sites, the nucleases comprising mutations in the cleavage domain (e.g., FokI or homologue thereof) and/or DNA binding domain (zinc finger protein, TALE, single guide RNA) such that on-target specificity for PD1 gene target sites is increased.

Status:
Application
Type:

Utility

Filling date:

18 Sep 2019

Issue date:

14 Oct 2021